ERBB2 and breast carcinoma: Anti-HER2 targeted therapies are crucial in treating HER2-positive breast cancer, including neoadjuvant therapy, adjuvant therapy, intensive adjuvant therapy for non-pCR patients, and salvage therapy for late-stage disease.